Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,203 trials

NCT07126119
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
Phase 2 · China · 1 site
Registry update: 17 Aug 2025
NCT07064681
Recruiting
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
Not applicable · China · 1 site
Registry update: 15 Jul 2025
NCT07048496
Recruiting
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
Not applicable · United States · 1 site
Registry update: 5 Oct 2026
NCT07167563
Recruiting
Real-world Lithium Intake
Not applicable · Denmark · 1 site
Registry update: 11 Sept 2025
NCT07612891
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Phase 1/2 · China · 1 site
Registry update: 29 May 2026
NCT07045064
Recruiting
Aerobic Versus Resistive Intradialytic Training Effect on Atherogeinc Index in Hemodialysis Patients
Not applicable · Egypt · 1 site
Registry update: 9 Jul 2025
2024-518289-28-00
Recruiting
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent
Phase 2 · Belgium, Czechia, Germany, Spain, France, Italy, Netherlands, Poland · 30 sites
Registry update: 15 Oct 2026
NCT06877299
Recruiting
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
Phase 2 · China · 1 site
Registry update: 2 Jan 2026
NCT07036796
Recruiting
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
Phase 2 · Egypt · 1 site
Registry update: 21 Jul 2026
NCT07177482
Recruiting
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Not applicable · China · 1 site
Registry update: 17 Sept 2025
2024-517789-41-00
Recruiting
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY
Phase 4 · Italy · 33 sites
Registry update: 17 Nov 2025
NCT07569458
Recruiting
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)
Not applicable · Denmark · 3 sites
Registry update: 6 May 2026
NCT07021963
Recruiting
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
Phase 2 · China · 1 site
Registry update: 10 Sept 2025
NCT06616987
Recruiting
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Phase 2 · South Korea · 1 site
Registry update: 28 Aug 2025
NCT07105852
Recruiting
Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
Phase 2 · China · 1 site
Registry update: 6 Aug 2025
NCT06864234
Recruiting
Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA
Phase 4 · Belgium · 1 site
Registry update: 14 Jul 2025
NCT07145450
Recruiting
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Phase 1/2 · Germany, Denmark, Netherlands, Sweden · 10 sites
Registry update: 8 Jun 2026
NCT07479095
Recruiting
Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma
Not applicable · Italy · 1 site
Registry update: 20 Mar 2026
NCT06942104
Recruiting
Imaging of Solid Tumors Using 18F-TRX
Phase 1 · United States · 1 site
Registry update: 23 Jul 2026
NCT06767657
Recruiting
Urgent Carotid Endarterectomy (CEA) Versus Delayed CEA in Symptomatic Carotid Stenosis (SPREAD-STACI II)
Not applicable · Italy · 1 site
Registry update: 4 Mar 2026

Ordered by registry start date. Freshness and sponsorship never change the order.